Forte Biosciences, Inc.
NASDAQ:FBRXBiotechnology
+$0.30 today
- Market cap
- $1.58B
- Beta
- 2.87
- P/E (TTM)
- -42.1
- EPS (TTM)
- -$0.43
Volume 0.00M
Average 0.30M
FBRX Accumulated OCI
Accumulated other comprehensive income: unrealized gains and losses, such as currency translation, recorded outside net income.
Forte Biosciences, Inc.NASDAQ: FBRX
Accumulated OCI · Q1 FY2026 · quarter ended Mar 2026
Accumulated OCI turns negative
Q1 FY2026 Accumulated OCI was -$4K, compared with $0 a year earlier.
Context
- Accumulated OCI amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Accumulated OCI increased in 2 of the last 3 fiscal years.
Sources:Balance SheetText generated from reported figures; not investment advice.
Accumulated OCI history
USD · from the balance sheet
- Latest · FY2025
- 3K USD
- Year-over-year change
- -72.7%
| Period | Period end | Accumulated OCI | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3K | -72.7% |
| FY2024 | 2024-12-31 | 11K | +175.0% |
| FY2023 | 2023-12-31 | 4K | — |
| FY2022 | 2022-12-31 | 0 | +100.0% |
| FY2021 | 2021-12-31 | (43.31M) | — |
Accumulated OCI vs competitors
How FBRX compares with its peers on the latest reported figures
- Peers report in different currencies, so Accumulated OCI is compared through growth and share of total assets rather than absolute size.
- Accumulated OCI amounts to 0.0% of total assets for FBRX, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | CHF 0 CHF | — | — | 0.0% | |
ACTUActuate Therapeutics Inc | Mar 2026 | $0 USD | — | — | 0.0% |
| Mar 2026 | -$4K USD | — | — | 0.0% | |
| Mar 2026 | -$49K USD | -281.5% | — | 0.1% | |
| Mar 2026 | -$59K USD | -168.2% | — | 0.0% | |
| Mar 2026 | -$77K USD | -140.3% | — | 0.0% | |
| Mar 2026 | -$104K USD | -154.5% | — | 0.0% | |
ELTXElicio Therapeutics, Inc. | Mar 2026 | -$122K USD | +15.3% | — | 0.5% |
| Mar 2026 | -$130K USD | -119.9% | — | 0.0% | |
| Mar 2026 | -$161K USD | -600.0% | — | 0.1% | |
| Peer median (excluding FBRX) | — | -154.5% | — | 0.0% | |
Competitors are the stored peer set for FBRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Forte Biosciences, Inc.
NASDAQ:FBRX
Intrinsic Alpha fair value
Locked
Current Price
$76.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.